vs
Side-by-side financial comparison of Hillenbrand, Inc. (HI) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $550.2M, roughly 1.1× Hillenbrand, Inc.). Royalty Pharma plc runs the higher net margin — 34.4% vs -0.4%, a 34.8% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs -22.2%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -16.3%).
Hillenbrand, Inc. is a global diversified industrial firm that designs, manufactures, and distributes specialized processing equipment and durable industrial solutions. It serves food & beverage, agriculture, manufacturing, waste management sectors, with operations across North America, Europe, and APAC.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
HI vs RPRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $550.2M | $622.0M |
| Net Profit | $-2.2M | $214.2M |
| Gross Margin | 33.4% | — |
| Operating Margin | -2.2% | 62.4% |
| Net Margin | -0.4% | 34.4% |
| Revenue YoY | -22.2% | 4.8% |
| Net Profit YoY | -134.4% | 2.9% |
| EPS (diluted) | — | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $550.2M | $622.0M | ||
| Q3 25 | $652.1M | $609.3M | ||
| Q2 25 | $598.9M | $578.7M | ||
| Q1 25 | $715.9M | $568.2M | ||
| Q4 24 | $706.9M | $593.6M | ||
| Q3 24 | $837.6M | $564.7M | ||
| Q2 24 | $786.6M | $537.3M | ||
| Q1 24 | $785.3M | $568.0M |
| Q4 25 | $-2.2M | $214.2M | ||
| Q3 25 | $75.7M | $288.2M | ||
| Q2 25 | $1.9M | $30.2M | ||
| Q1 25 | $-40.9M | $238.3M | ||
| Q4 24 | $6.4M | $208.2M | ||
| Q3 24 | $14.6M | $544.0M | ||
| Q2 24 | $-248.9M | $102.0M | ||
| Q1 24 | $6.1M | $4.8M |
| Q4 25 | 33.4% | — | ||
| Q3 25 | 34.8% | — | ||
| Q2 25 | 33.8% | — | ||
| Q1 25 | 33.0% | — | ||
| Q4 24 | 33.2% | — | ||
| Q3 24 | 34.4% | — | ||
| Q2 24 | 33.9% | — | ||
| Q1 24 | 31.9% | — |
| Q4 25 | -2.2% | 62.4% | ||
| Q3 25 | — | 70.1% | ||
| Q2 25 | 1.8% | 36.3% | ||
| Q1 25 | -6.2% | 94.0% | ||
| Q4 24 | 2.2% | 60.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | -32.7% | 50.2% | ||
| Q1 24 | 1.6% | -13.0% |
| Q4 25 | -0.4% | 34.4% | ||
| Q3 25 | 11.6% | 47.3% | ||
| Q2 25 | 0.3% | 5.2% | ||
| Q1 25 | -5.7% | 41.9% | ||
| Q4 24 | 0.9% | 35.1% | ||
| Q3 24 | 1.7% | 96.3% | ||
| Q2 24 | -31.6% | 19.0% | ||
| Q1 24 | 0.8% | 0.8% |
| Q4 25 | — | $0.49 | ||
| Q3 25 | $1.07 | $0.67 | ||
| Q2 25 | $0.03 | $0.07 | ||
| Q1 25 | $-0.58 | $0.55 | ||
| Q4 24 | $0.09 | $0.46 | ||
| Q3 24 | $0.20 | $1.21 | ||
| Q2 24 | $-3.53 | $0.23 | ||
| Q1 24 | $0.09 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $173.1M | $618.7M |
| Total DebtLower is stronger | — | $9.0B |
| Stockholders' EquityBook value | $1.4B | $9.7B |
| Total Assets | $4.5B | $19.6B |
| Debt / EquityLower = less leverage | — | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $173.1M | $618.7M | ||
| Q3 25 | $164.8M | $938.9M | ||
| Q2 25 | $162.8M | $631.9M | ||
| Q1 25 | $458.4M | $1.1B | ||
| Q4 24 | $208.0M | $929.0M | ||
| Q3 24 | $199.3M | $950.1M | ||
| Q2 24 | $223.8M | $1.8B | ||
| Q1 24 | $224.4M | $843.0M |
| Q4 25 | — | $9.0B | ||
| Q3 25 | $1.5B | $8.9B | ||
| Q2 25 | $1.7B | $8.0B | ||
| Q1 25 | $1.9B | $7.6B | ||
| Q4 24 | $1.9B | $7.6B | ||
| Q3 24 | $1.9B | $7.6B | ||
| Q2 24 | $2.1B | $7.6B | ||
| Q1 24 | $2.1B | $6.1B |
| Q4 25 | $1.4B | $9.7B | ||
| Q3 25 | $1.4B | $9.6B | ||
| Q2 25 | $1.3B | $9.5B | ||
| Q1 25 | $1.3B | $9.8B | ||
| Q4 24 | $1.4B | $10.3B | ||
| Q3 24 | $1.4B | $10.3B | ||
| Q2 24 | $1.4B | $9.8B | ||
| Q1 24 | $1.7B | $9.9B |
| Q4 25 | $4.5B | $19.6B | ||
| Q3 25 | $4.5B | $19.3B | ||
| Q2 25 | $4.7B | $18.3B | ||
| Q1 25 | $4.8B | $17.6B | ||
| Q4 24 | $5.1B | $18.2B | ||
| Q3 24 | $5.2B | $18.0B | ||
| Q2 24 | $5.3B | $17.7B | ||
| Q1 24 | $5.6B | $16.1B |
| Q4 25 | — | 0.92× | ||
| Q3 25 | 1.10× | 0.93× | ||
| Q2 25 | 1.27× | 0.84× | ||
| Q1 25 | 1.44× | 0.78× | ||
| Q4 24 | 1.38× | 0.74× | ||
| Q3 24 | 1.33× | 0.74× | ||
| Q2 24 | 1.48× | 0.78× | ||
| Q1 24 | 1.28× | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-27.4M | $827.1M |
| Free Cash FlowOCF − Capex | $-31.6M | — |
| FCF MarginFCF / Revenue | -5.7% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | — | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $7.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-27.4M | $827.1M | ||
| Q3 25 | $67.7M | $702.6M | ||
| Q2 25 | $-1.5M | $364.0M | ||
| Q1 25 | $1.3M | $596.1M | ||
| Q4 24 | $-11.3M | $742.5M | ||
| Q3 24 | $166.5M | $703.6M | ||
| Q2 24 | $45.6M | $658.2M | ||
| Q1 24 | $3.2M | $664.6M |
| Q4 25 | $-31.6M | — | ||
| Q3 25 | $58.6M | — | ||
| Q2 25 | $-11.2M | — | ||
| Q1 25 | $-8.0M | — | ||
| Q4 24 | $-21.5M | — | ||
| Q3 24 | $153.4M | — | ||
| Q2 24 | $29.7M | — | ||
| Q1 24 | $-9.6M | — |
| Q4 25 | -5.7% | — | ||
| Q3 25 | 9.0% | — | ||
| Q2 25 | -1.9% | — | ||
| Q1 25 | -1.1% | — | ||
| Q4 24 | -3.0% | — | ||
| Q3 24 | 18.3% | — | ||
| Q2 24 | 3.8% | — | ||
| Q1 24 | -1.2% | — |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 1.4% | — | ||
| Q2 25 | 1.6% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.4% | — | ||
| Q3 24 | 1.6% | — | ||
| Q2 24 | 2.0% | — | ||
| Q1 24 | 1.6% | — |
| Q4 25 | — | 3.86× | ||
| Q3 25 | 0.89× | 2.44× | ||
| Q2 25 | -0.79× | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | -1.77× | 3.57× | ||
| Q3 24 | 11.40× | 1.29× | ||
| Q2 24 | — | 6.45× | ||
| Q1 24 | 0.52× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HI
| Transferred At Point In Time | $256.5M | 47% |
| Transferred Over Time | $207.1M | 38% |
| Molding Technology Solutions | $86.6M | 16% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
